section name header

Pronunciation ⬇

lee-vo-loo-koe-VOR-in KAL-see-um

Classifications ⬆ ⬇

Therapeutic Classification: antidotes (for methotrexate), vitamins

Pharmacologic Classification: folic acid analogues

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • The reduced form of folic acid that serves as a cofactor in the synthesis of DNA and RNA; does not require dihydrofolate reductase for activity.
Therapeutic effects:
  • Reversal of toxic effects of folic acid antagonists, including methotrexate, that inhibit dihydrofolate reductase.
  • Improved performance status in patients with colorectal cancer.

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results on complete bioavailability.

Distribution: Transported actively and passively across cell membranes; enters CSF.

Metabolism/Excretion: Extensively converted to tetrahydrofolic derivatives.

Half-Life: Total tetrahydrofolic acid: 5.1 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
IVunknownend of infusion3–6 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: dermatitis

GI: nausea, stomatitis, vomiting, altered taste, diarrhea, dyspepsia

GU: renal impairment

Neuro: confusion, neuropathy

Resp: dyspnea

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Levoleucovorin Rescue Following High-Dose Methotrexate—Based on a Methotrexate Dose of 12 g/m2 IV Over 4 hr and Concurrent with Hydration and Maintenance of Urine pH 7.0

Levoleucovorin Rescue Following Inadvertent Overdosage of Methotrexate

Palliative Treatment of Advanced Metastatic Colorectal Cancer

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Khapzory

Code ⬆

NDC Code